Sentinel Node Mapping in High Risk Endometrial Cancer
Recruiting
N/A
Interventional Study
Endometrial Cancer
Lymph Node Metastases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Female
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 178 (estimated)
- Sponsor
- AC Camargo Cancer Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study will evaluate the role of systematic lymphadenectomy after sentinel node (SLN) mapping in high risk endometrial cancer (high grade histologies or deep myometrial invasion). The participants will be randomized in a non-inferiority controlled trial in 2 groups: SLN mapping or SLN mapping followed by systematic lymphadenectomy.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* High grade histologies (endometrioid grade 3, serous, clear cell and carcinosarcoma)
* Endometrioid grades 1 or 2 with myometrial invasion of ≥50%
* Endometrioid grades 1 or 2 with cervical invasion
* Clinically suitable to receive systematic lymphadenectomy
* Consent statemen…
Contacts